What Is Oncology?

Oncology is a branch of medicine concerned with the study, diagnosis, treatment, and prevention of cancer. It encompasses the biology of malignant disease, the clinical management of patients with cancer, and the development of new therapeutic and diagnostic technologies. Oncologists work across three primary subspecialties: medical oncology, which oversees systemic treatments including chemotherapy, targeted therapy, and immunotherapy; radiation oncology, which deploys ionizing radiation to damage tumor DNA; and surgical oncology, which removes solid tumors and performs staging procedures. Hematologic oncology further addresses malignancies of the blood and lymphatic system.

Cancer represents a collection of diseases characterized by the uncontrolled proliferation of abnormal cells with the capacity to invade adjacent tissues and metastasize to distant sites. Globally, cancer is among the leading causes of mortality, with approximately 10 million deaths attributed to the disease annually according to the World Health Organization, making oncology one of the most resource-intensive areas of biomedical research and clinical care.

Cancer Biology and Classification

Understanding oncology requires knowledge of the molecular mechanisms that drive malignant transformation. Oncogenes, tumor suppressor genes, and DNA repair pathways form the genetic machinery that, when disrupted by mutation, epigenetic change, or chromosomal rearrangement, converts normal cells into cancer cells. Somatic mutations in genes such as TP53, KRAS, BRCA1, and BRCA2 recur across many cancer types and serve as both diagnostic markers and therapeutic targets. Cancer classification systems categorize tumors by anatomical origin, histological type (carcinoma, sarcoma, lymphoma, leukemia), and molecular profile. The TNM staging system, maintained by the American Joint Committee on Cancer, describes tumor size, lymph node involvement, and distant metastasis to produce a standardized stage that guides prognosis and treatment selection. The NIH National Cancer Institute's principles of cancer treatment provides foundational definitions that underpin clinical decision-making across oncology subspecialties.

Diagnostic Methods

Accurate diagnosis is the foundation of oncological care. Histopathological examination of biopsy specimens, assessed under light microscopy and supplemented by immunohistochemistry, determines the cell type and grade of the tumor. Advanced imaging modalities, including positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT), locate primary and metastatic disease and assess treatment response. Molecular diagnostics have expanded the information available from each specimen: high-throughput sequencing (NGS) panels identify actionable somatic mutations, copy number variations, and fusion genes within a single assay, enabling oncologists to match patients with targeted therapies that address the specific molecular driver of their cancer. Liquid biopsy techniques, which detect circulating tumor DNA and circulating tumor cells in peripheral blood, provide a non-invasive means of monitoring disease burden and treatment response over time. Research documented in PMC and NIH publication databases on engineering approaches to cancer diagnosis reviews the expanding role of bioengineered sensors and assays in clinical oncology diagnostics.

Treatment Modalities

Surgery, radiation, and systemic therapy are the three principal treatment categories, frequently deployed in combination. Cytotoxic chemotherapy disrupts cell division through DNA alkylation, antimetabolite interference, or mitotic spindle inhibition. Targeted therapies such as tyrosine kinase inhibitors and monoclonal antibodies act on specific molecular vulnerabilities identified in the tumor's genomic profile. Immune checkpoint inhibitors, including pembrolizumab (targeting PD-1) and ipilimumab (targeting CTLA-4), release immunological brakes to allow the patient's own T cells to recognize and destroy tumor cells. CAR-T cell therapy engineers the patient's T lymphocytes ex vivo to express chimeric antigen receptors specific to tumor antigens, achieving durable remissions in certain hematologic malignancies. The intersection of oncology and biomedical engineering is explored in the NIH National Cancer Institute's cancer bioengineering program at CCR, which coordinates research on imaging agents, drug delivery systems, and tumor microenvironment modeling.

Applications

Oncology has applications in a range of fields, including:

• Pharmaceutical development, for the discovery and clinical testing of cytotoxic, targeted, and immunological cancer therapies
• Biomedical imaging systems, including PET-CT and MRI hardware designed for tumor detection and treatment planning
• Radiation therapy physics, covering dosimetry, linear accelerator design, and proton beam therapy
• AI-assisted pathology and radiology, applying deep learning to tumor segmentation and biomarker identification
• Implantable drug delivery devices, enabling localized, sustained chemotherapy release at the tumor site